Progesterone receptor expression is an independent prognostic variable in early breast cancer: A population-based study

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 565-572

  Purdie, C A ^a   Quinlan, P ^a   Jordan, L B ^a   Ashfield, A ^a   Ogston, S ^b   Dewar, J A ^a   Thompson, A M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

biomarker; breast cancer; predictive testing; progesterone receptor; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; YOUNG ADULT;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893775517     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.756     Document Type: Article

References (44)

1. Arpino G, Weiss H, Lee A, Schiff R, De Placido S, Osborne C, Elledge R (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97: 1254-1261.
2. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21: 1973-1979.
3. Blamey R, Davies C, Elston C, Johnson J, Haybittle J, Maynard P (1979) Prognostic factors in breast cancer-the formation of a prognostic index. Clin Oncol 5: 227-236.
4. Breast International Group (BIG) 1-98 Collaborative GroupThürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Wardly A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757.
5. BSP (2005) Pathology Reporting of Breast DiseaseNHS BSP: Sheffield 1-144, Publication No 58.
6. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
7. Creighton C, Kent Osborne C, van de Vijver M, Foekens J, Klijn J, Horlings H, Nuyten D, Wang Y, Zhang Y, Chamness G, Hilsenbeck S, Lee A, Schiff R (2009) Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114: 287-299.
8. Detre S, Saclani Jotti G, Dowsett M (1995) A 'quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878.
9. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac A, Knox F, Speirs V, Forbes J, Buzdar A (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26: 1059-1065.
10. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23: 7512-7517.
11. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I (2001) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61: 8452-8458.
12. Dowsett M, Nielsen TO, A'hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of ki67 in breast cancer: recommendations from the international ki67 in breast cancer working group. J Natl Cancer Inst 103: 1656-1664.
13. Ellis I, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B, Mallon E, Lee P (2000) Recommendations for HER2 testing in the UK. J Clin Pathol 53: 890-892.
14. Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JMS (2009) Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience. Histopathology 55: 587-593.
15. Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526.
16. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology, College of American Pathologists (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: e48-e72.
17. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
18. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45: 361-366.
19. Horwitz KB, McGuire WL (1975) Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189: 726-727.
20. Horwitz KB, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253: 2223-2228.
21. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE (2012) Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 30: 718-721.
22. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, Overgaard J (2008) Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 47: 591-599.
23. Liu S, Chia S, Mehl E, Leung S, Rajput A, Cheang M, Nielsen T (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119: 53-61.
24. MacGrogan G, de Mascarel I, Sierankowski G, Mauriac L, Debled M, Durand M, De Lara CT, Avril A, Picot V, Mathoulin-Pélissier S (2005) Time for reappraisal of progesterone-receptor testing in breast cancer management. J Clin Oncol 23: 2870-2871; authorreply2871.
25. Mann GB, Fahey VD, Feleppa F, Buchanan MR (2005) Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23: 5148-5154.
26. Mohsin S, Weiss H, Havighurst T, Clark G, Berardo M, Roanh le D, To T, Qian Z, Love R, Allred D (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17: 1545-1554.
27. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, van't Veer LJ, Ravdin PM (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10: 1070-1076.
28. National Institute for Health, and Excellence (2009) CG80 Early and locally advanced breast cancer: full guideline (NICE). Olivotto I, Truong P, Speers C, Bernstein V, Allan S, Kelly S, Lesperance M (2004) Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22: 1769-1770.
29. Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, Adamson DJA, Dewar JA, Thompson AM (2010a) Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer 103: 475-481.
30. Purdie CA, Jordan LB, McCullough JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N, Thompson AM (2010b) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56: 702-707.
31. Rakha EA, El-SayedME, LeeAHS, Elston CW, GraingeMJ, Hodi Z, Blamey RW, Ellis IO (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26: 3153-3158.
32. Ravdin P, Green S, Dorr T, McGuire W, Fabian C, Pugh R, Carter R, Rivkin S, Borst J, Belt R, Metch B, Osborne CK (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291.
33. SIGN (2007) S.I.G.N.Management of breast cancer in women. (SIGN Guideline No 84) 1-52. Stendahl M, Ryden L, Nordenskjold B, Jonsson P, Landberg G, Jirstrom K (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12: 4614-4618.
34. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
35. Thakkar JP, Mehta DG (2011) A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16: 276-285.
36. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA. Breast Recurrence in Tissues Study Group (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12: R92.
37. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256.
38. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
39. van t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
40. Viale G, Regan M, Maiorano E, Mastropasqua M, Dell'Orto P, Rasmussen B, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber R, Castiglione-Gertsch M, Price K, Goldhirsch A, Gusterson B, Coates A (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25: 3846-3852.
41. Walker RA, Bartlett JMS, Dowsett M, Ellis IO, Hanby AM, Jasani B, Miller K, Pinder SE (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61: 818-824.
42. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98: 11462-11467.
43. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183.
44. Yu WC, Leung BS, Gao YL (1981) Effects of 17 beta-estradiol on progesterone receptors and the uptake of thymidine in human breast cancer cell line CAMA-1. Cancer Res 41: 5004-5009.